Camrelizumab, initially known as SHR-1210, represents a significant advancement in malignant treatment, functioning as a monoclonal that inhibits the programmed PD-1 receptor. This control protein, expressed on T cells, normally suppresses anti-tumor immune responses, allowing malignant tissues to evade identification by the body’s defenses . By